Galanthamine, probably the most important Amaryllidaceae alkaloid, is FDA approved since 2001 for the palliative treatment of mild to moderate Alzheimer’s disease symptomatology because of its ability as an acetylcholinesterase inhibitor [21,22]. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.